8-K: Seelos Therapeutics and Lind Global Amend Convertible Note Agreement to Address Nasdaq Listing Requirements

Seelos Therapeutics has entered into an agreement with Lind Global Asset Management to convert a $22 million convertible note into common stock upon a fundamental transaction, aiming to meet Nasdaq's continued listing standards.

Summary

• Seelos Therapeutics has reached an agreement with Lind Global Asset Management V, LLC regarding a convertible promissory note.
• The original note, with a principal amount of $22 million, was issued in 2021.
• The new agreement stipulates that upon a 'Fundamental Transaction', the outstanding balance of the note will be converted into shares of Seelos' common stock.
• The conversion price per share will be determined at the time of conversion.
• This conversion is intended to help Seelos comply with Nasdaq's continued listing requirements related to stockholders' equity.
• The agreement ensures that the conversion will not result in Lind Global exceeding the ownership cap specified in the original note.
• The agreement includes standard representations and warranties from both parties.

Sentiment

Score: 6

Explanation: The agreement is a necessary step for Seelos to maintain its Nasdaq listing, but it introduces uncertainty and potential dilution. The sentiment is neutral to slightly positive as it addresses a critical issue but does not guarantee success.

Positives

• The agreement provides a pathway for Seelos to meet Nasdaq's continued listing requirements.
• The conversion of the note into equity could improve the company's balance sheet.
• The agreement includes standard protections for both parties through representations and warranties.

Negatives

• The conversion is contingent on a 'Fundamental Transaction' occurring, which introduces uncertainty.
• The conversion price is not fixed and will be determined at a later date, which could be unfavorable to Seelos.
• The agreement is subject to continued listing on Nasdaq and compliance with all applicable laws and regulations.

Risks

• The company's ability to remain listed on the Nasdaq is still dependent on the successful execution of a 'Fundamental Transaction'.
• The conversion price is not yet determined, which could lead to dilution of existing shareholders.
• There is a risk that the 'Fundamental Transaction' may not occur or may not be on terms favorable to Seelos.

Future Outlook

The agreement is designed to facilitate Seelos' compliance with Nasdaq listing requirements, but the actual conversion is dependent on a future 'Fundamental Transaction'.

Management Comments

• The agreement is intended to enable the Company to comply with the continued listing standard set forth in Rule 5550(a) of the Nasdaq Capital Market listing requirements relating to the Company's stockholders equity.

Industry Context

This type of agreement is not uncommon for companies facing potential delisting due to low stock prices or insufficient equity. It is a way to restructure debt and potentially improve the company's financial position.

Comparison to Industry Standards

• Many biotech companies with low market capitalization use convertible notes as a form of financing.
• The use of a 'Fundamental Transaction' as a trigger for conversion is a common mechanism to align the interests of the noteholder with the company's strategic direction.
• The specific terms of the conversion, such as the conversion price and ownership cap, are typical in these types of agreements.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the note.
• The agreement is intended to help the company maintain its Nasdaq listing, which is important for shareholder value.
• The company's financial stability could be improved by reducing debt and increasing equity.

Next Steps

• Seelos needs to execute a 'Fundamental Transaction' that is agreeable to Lind Global.
• The conversion price per share needs to be agreed upon by both parties.
• The company must continue to comply with Nasdaq listing requirements and all applicable laws and regulations.

Key Dates

Keywords

convertible note, fundamental transaction, Nasdaq listing, stockholders equity, Lind Global, Seelos Therapeutics, conversion agreement